DEFA14A: Edgewise Therapeutics Appoints Arlene Morris to Board of Directors

Edgewise Therapeutics appoints Arlene Morris, a biotech industry veteran, to its Board of Directors, effective May 6, 2024.

Summary

• Edgewise Therapeutics appointed Arlene Morris to its Board of Directors on May 6, 2024.
• Ms. Morris will serve as a Class I director, with her term expiring at the company's 2025 annual meeting of stockholders.
• She will also be a member of the Audit Committee and the Compensation Committee, replacing Peter Thompson.
• Ms. Morris has served as Chief Executive Officer of Willow Advisors since 2015.
• She previously held CEO positions at Syndax Pharmaceuticals and Affymax Inc.
• Ms. Morris currently serves on the boards of Cogent Biosciences, Palatin Technologies, Viridian Therapeutics, and TC BioPharm (Holdings) PLC.
• She received a B.A. in Biology and Chemistry from Carlow College.
• The Board determined that Ms. Morris qualifies as an independent director under SEC and Nasdaq rules.
• Ms. Morris will receive an annual cash retainer of $40,000 for her service as an outside director.
• She will also receive additional retainers of $7,500 and $5,000 per year for her service on the Audit and Compensation Committees, respectively.
• Ms. Morris was granted a stock option with a grant date fair value of approximately $500,000, vesting monthly over three years.
• She also executed the company's standard form of indemnification agreement.

Sentiment

Score: 7

Explanation: The announcement is positive due to the addition of an experienced director, but it's a routine corporate governance matter.

Positives

• The appointment of Arlene Morris brings extensive experience and leadership to Edgewise Therapeutics' Board.
• Ms. Morris's expertise in financing, strategy, and business development could benefit the company.
• Her experience as a CEO of public biotechnology companies is a valuable asset.
• The Board has determined that Ms. Morris qualifies as an independent director, ensuring objectivity and compliance.

Future Outlook

The company expects Ms. Morris to be a valued advisor as they continue to advance their mission of changing the lives of patients and families affected by serious muscle diseases.

Management Comments

• Kevin Koch, Ph.D., President and Chief Executive Officer, stated that Arlene brings invaluable expertise in strategic development and operational excellence.

Industry Context

The appointment of a seasoned biotech executive like Arlene Morris reflects a common strategy in the biopharmaceutical industry to strengthen leadership and governance, particularly as companies advance clinical programs and seek financing.

Comparison to Industry Standards

• Compensation for outside directors at similar-stage biotech companies typically includes a mix of cash retainers and equity grants.
• The annual cash retainer of $40,000 for Ms. Morris is within the typical range for companies of Edgewise Therapeutics' size and stage.
• The stock option grant with a fair value of $500,000 is also a common practice to align the director's interests with those of shareholders.
• Companies like Viridian Therapeutics, where Ms. Morris also serves as a director, follow similar compensation practices for their board members.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment positively, as it strengthens the Board's expertise.
• Employees may benefit from Ms. Morris's experience in strategic development and operational excellence.
• The appointment does not directly impact customers, suppliers, or creditors.

Key Dates

Keywords

Board of Directors, Arlene Morris, Edgewise Therapeutics, Appointment, Director, Biotechnology, Pharmaceutical, Audit Committee, Compensation Committee